Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer.
Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.
Ideta
Ryuichi
R
Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tasaka
Fumitaka
F
Jang
Woo-Dong
WD
Nishiyama
Nobuhiro
N
Zhang
Guo-Dong
GD
Harada
Atsushi
A
Yanagi
Yasuo
Y
Tamaki
Yasuhiro
Y
Aida
Takuzo
T
Kataoka
Kazunori
K
D000818:Animals; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D015355:Glaucoma, Neovascular / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D046911:Macromolecular Substances / Q000737:chemistry; D008297:Male; D036103:Nanotechnology / Q000379:methods*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011166:Porphyrins / Q000008:administration & dosage* / Q000737:chemistry; D051381:Rats
D004337:Drug Carriers; D046911:Macromolecular Substances; D017319:Photosensitizing Agents; D011166:Porphyrins